Skip to Content
Living with HIV? Check out the patient's guide to HIV

Zalcitabine Pregnancy and Breastfeeding Warnings

Zalcitabine is also known as: Hivid

Zalcitabine Pregnancy Warnings

An Antiretroviral Pregnancy Registry has been established to monitor maternal:fetal outcomes of zalcitabine exposures during pregnancy. To register patients, physicians should call 800-526-6367.

Zalcitabine has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of embryolethality and teratogenicity at high doses. There are no controlled data in human pregnancy. Zalcitabine should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Zalcitabine Breastfeeding Warnings

There are no data on the excretion of zalcitabine into human milk. HIV-infected mothers should not breast-feed their infants due to the risk of transmission of HIV via breast milk.

See references

References for pregnancy information

  1. Perinatal HIV Guidelines Working Group "Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL:" ([2008 Jul 8]):
  2. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  3. "Product Information. HIVID (zalcitabine)." Roche Laboratories, Nutley, NJ.

References for breastfeeding information

  1. Newell ML, Dunn D, Peckham CS, Ades AE, Pardi G, Semprini AE "Risk factors for mother-to-child transmission of HIV-1." Lancet 339 (1992): 1007-12
  2. Fairbrothers D, Kirby E, Lester RM, Wegmann PC, Marshall F, Parkin WE "Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and AIDS." MMWR Morb Mortal Wkly Rep 34 (1985): 721-34
  3. "Product Information. HIVID (zalcitabine)." Roche Laboratories, Nutley, NJ.
  4. Public Health Service Task Force, Perinatal HIV Guidelines Working Group "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available from: URL:" ([2004 Dec 17]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.